Skip to main content

Table 4 Factors associated with the mortality of patients with subsequent CRE infection

From: Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization

Variables

Mortality group (N = 6)

Survival group (N = 12)

P-value

Demographics

   

Age (X ± SD, years)

53.8 ± 24.2

31.4 ± 19.4

0.050

Sex, male

4 (66.7)

6 (50.0)

0.638

Hospitalization

   

Length of stay, (IQR, days)

4 (66.7)

10 (83.3)

0.569

Transferring from another hospital

1 (16.7)

2 (16.7)

1.000

Admission to ICU

2 (33.3)

4 (33.3)

1.000

Prior hospitalization

5 (83.3)

8 (66.7)

0.615

Comorbid conditions

  

1.000

Diabetes mellitus

1 (16.7)

1 (8.3)

1.000

Solid tumor

1 (16.7)

1 (8.3)

1.000

Pneumonia

5 (83.3)

9 (75.0)

1.000

Liver disease

4 (66.7)

5 (41.7)

0.620

Gastritis

2 (33.3)

2 (16.7)

0.569

Shock

6 (100.0)

2 (16.7)

0.002*

Diarrhea

4 (66.7)

9 (75.0)

1.000

Invasive procedures

   

Central venous catheter

4 (66.7)

10 (83.3)

0.569

Arterial catheter

2 (33.3)

2 (16.7)

0.569

Endotracheal intubation

2 (33.3)

0 (0.0)

0.098

Mechanical ventilation

4 (66.7)

6 (50.0)

0.638

Urinary catheter

2 (33.3)

2 (16.7)

0.569

Nasogastric tube

3 (50.0)

1 (8.3)

0.083

HSCT

0 (0.0)

5 (41.7)

0.114

Drug exposure

   

PPIs

4 (66.7)

11 (91.7)

0.245

Glucocorticoid

5 (83.3)

8 (66.7)

0.615

Cephalosporins

1 (16.7)

5 (41.7)

0.600

Carbapenems

6 (100.0)

11 (91.7)

1.000

Fluoroquinolones

1 (16.7)

8 (66.7)

0.131

Glycopeptides

2 (33.3)

7 (58.3)

0.620

Tigecycline

2 (33.3)

6 (50.0)

0.638

Oxazolidones

1 (16.7)

5 (41.7)

0.600

Aminoglycosides

0 (0.0)

3 (25.0)

0.515

β-lactam/β-lactamase inhibitors

4 (66.7)

8 (66.7)

1.000

Macrolides

0 (0.0)

2 (16.7)

0.529

Antiviral agents

1 (16.7)

6 (50.0)

0.316

CRE isolates

   

Klebsiella pneumoniae

5 (83.3)

5 (41.7)

0.240

Escherichia coli

1 (16.7)

5 (41.7)

0.596

Enterobacter cloacae

0 (0.0)

1 (8.3)

0.480

others

0 (0.0)

1 (8.3)

0.480

Type of hematological malignancy

   

AML

1 (16.7)

7 (58.3)

0.240

ALL

2 (33.3)

4 (33.3)

1.000

Lymphoma

3 (50.0)

1 (8.3)

0.161

Antimicrobial susceptibility profiles

   

Resistant to all the tested antimicrobial agents

0 (0.0)

1 (8.3)

1.000

Resistant to amikacin

6 (100.0)

10 (83.3)

0.529

Resistant to tigecyclin

6 (100.0)

10 (83.3)

1.000

Resistant to colistin

0 (0.0)

1 (8.3)

0.529

Antimicrobial treatment

   

Carbapenems + amikacin

1 (16.7)

5 (41.7)

0.600

Carbapenems + tigecyclin

3 (50.0)

6 (50.0)

1.000

Carbapenems + colistin

1 (16.7)

2 (16.7)

1.000

Carbapenems + amikacin + tigecyclin

3 (50.0)

4 (33.3)

1.000

Carbapenems + tigecyclin + colistin

3 (50.0)

4 (33.3)

0.627

Carbapenems + amikacin + tigecyclin + colistin

1 (8.3)

0(0.0)

1.000

  1. Values are presented as n(%), unless otherwise noted
  2. OR, odds ration; CI, confidence interval; ICU, intensive care unit; CRE, Carbapenem-resistant Enterobacterales; HSCT, hematopoietic stem cell transplantation; PPI, proton pump inhibitors; TMP/SMX, sulfamethoxazole and trimethoprim; AML, Acute Myeloid Leukemia; ALL, Acute Lymphoblastic Leukemia
  3. * Statistically significant differences between groups (P < 0.05)